Nevirapine (NVP) Use to Prevent Mother-to-Child Transmission of HIV
HIV Infections
About this trial
This is an interventional prevention trial for HIV Infections focused on measuring Maternal/Infant Transmisson, Vertical Transmission, Pregnancy, HIV Seronegativity
Eligibility Criteria
Inclusion Criteria: HIV infection, documented on two separate specimens Estimated gestational age at enrollment of 32 weeks or more as indicated by last menstrual cycle and fundal height Permanent residency in Addis Ababa Plan to deliver at a hospital affliated with the study (Tikur Anbessa Hospital, Gandhi hospital, or St. Paul's Hospital) Hemoglobin >= 7.5 gm/dl within 4 weeks prior to study entry Serum glutamic pyruvic transaminase (SGPT) < 5 times upper limit of normal within 4 weeks prior to study entry Serum creatinine < 1.5 mg/dl within 4 weeks prior to study entry Consent form signed by the mother and, when possible, by the father, prior to the onset of labor
Sites / Locations
- Tikur Anbessa Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
1
2
Participants will receive nevirapine for 6 weeks
Participants will receive nevirapine placebo for 6 weeks